Histogen, a regenerative medicine biotech in San Diego, has a new CEO and chairman.
The company tapped Richard Pascoe, who will lead the company at what he called a pivotal time.
Chiefly, Histogen this year will read out final-stage data on HSC660, its lead drug candidate for hair loss.
Previously, he was the CEO of Apricus Biosciences, which is set to merge with Seelos Therapeutics, it was announced mid-month. Before Apricus, Pascoe was the CEO of Somaxon Pharmaceuticals and COO of ARIAD Pharmaceuticals, among other positions.
Pascoe served as a commissioned officer with the U.S. Army 24th Infantry Division where he earned a Bronze Star Medal during Operation Desert Storm. He received a bachelor’s in leadership from the United States Military Academy at West Point.
He sits on the board of Biocom – and others.
Gail Naughton, Histogen’s founder, and CEO until mid-2017, is currently the company’s chief science officer and chief business development officer.
Life sciences and health care reporter Jared Whitlock can be reached at firstname.lastname@example.org or 858-634-4636.